Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
New new contracts, summarized for you
No login, no app to check — it comes to you
See who's moving and how much in your market
Liquidia Corporation Amends HealthCare Royalty Agreement to Add Up to $100 Million
Contract Type
agreement
MorrisvilleManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnology ResearchDescription
Liquidia Corporation has entered into a sixth amendment to its agreement with HealthCare Royalty to provide for up to an additional $100 million of financing in three tranches. The proceeds will be used to fund ongoing commercial development of YUTREPIA™ (treprostinil) inhalation powder for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), continued development of YUTREPIA in other clinical trials, clinical development of L606, and for general corporate purposes.